293 related articles for article (PubMed ID: 19212618)
1. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
[TBL] [Abstract][Full Text] [Related]
2. Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis.
Bai Z; Ye Y; Chen D; Shen D; Xu F; Cui Z; Wang S
APMIS; 2007 Dec; 115(12):1383-90. PubMed ID: 18184409
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of osteopontin expression in human gastric carcinoma.
Higashiyama M; Ito T; Tanaka E; Shimada Y
Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
[TBL] [Abstract][Full Text] [Related]
5. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis.
Mizoshita T; Tsukamoto T; Nakanishi H; Inada K; Ogasawara N; Joh T; Itoh M; Yamamura Y; Tatematsu M
J Cancer Res Clin Oncol; 2003 Dec; 129(12):727-34. PubMed ID: 14557879
[TBL] [Abstract][Full Text] [Related]
6. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
7. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.
Tang H; Wang J; Bai F; Zhai H; Gao J; Hong L; Xie H; Zhang F; Lan M; Yao W; Liu J; Wu K; Fan D
Cancer Invest; 2008 Feb; 26(1):60-7. PubMed ID: 18181047
[TBL] [Abstract][Full Text] [Related]
8. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
9. CDX2 as a prognostic marker in gastric cancer.
Masood MA; Loya A; Yusuf MA
Acta Gastroenterol Belg; 2016; 79(2):197-200. PubMed ID: 27382937
[TBL] [Abstract][Full Text] [Related]
10. CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype.
Ha Kim G; Am Song G; Youn Park D; Han Lee S; Hyun Lee D; Oh Kim T; Jae Jo H; Heo J; Hwan Kang D; Cho M
Scand J Gastroenterol; 2006 Aug; 41(8):880-6. PubMed ID: 16803685
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
[TBL] [Abstract][Full Text] [Related]
12. [Expression of osteopontin mRNA and its clinical significance in gastric cancer].
Sun XJ; Zuo WS; Ma H; Hou WH; Cai SP; Jiang XH
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):292-5. PubMed ID: 15996323
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
14. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression.
Lin CN; Wang CJ; Chao YJ; Lai MD; Shan YS
BMC Cancer; 2015 Mar; 15():128. PubMed ID: 25872762
[TBL] [Abstract][Full Text] [Related]
15. Cdx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas.
Matsumoto K; Mizoshita T; Tsukamoto T; Ogasawara N; Hirata A; Shimizu Y; Haneda M; Yamao K; Tatematsu M
Oncol Rep; 2004 Dec; 12(6):1239-43. PubMed ID: 15547744
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.
Ito R; Oue N; Yoshida K; Kunimitsu K; Nakayama H; Nakachi K; Yasui W
Virchows Arch; 2005 Oct; 447(4):717-22. PubMed ID: 16044349
[TBL] [Abstract][Full Text] [Related]
17. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
[TBL] [Abstract][Full Text] [Related]
18. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance.
Park DY; Srivastava A; Kim GH; Mino-Kenudson M; Deshpande V; Zukerberg LR; Song GA; Lauwers GY
Mod Pathol; 2010 Jan; 23(1):54-61. PubMed ID: 19820687
[TBL] [Abstract][Full Text] [Related]
19. Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers.
Hirano N; Tsukamoto T; Mizoshita T; Koriyama C; Akiba S; Campos F; Carrasquilla G; Carrascal E; Cao X; Toyoda T; Ban H; Miki K; Tatematsu M
Histol Histopathol; 2007 Jun; 22(6):641-9. PubMed ID: 17357094
[TBL] [Abstract][Full Text] [Related]
20. Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma.
Satake S; Semba S; Matsuda Y; Usami Y; Chiba H; Sawada N; Kasuga M; Yokozaki H
Pathol Int; 2008 Mar; 58(3):156-63. PubMed ID: 18251778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
